Hematopoietic and Lymphoid Cell NeoplasmNCT05132842
Cannabis Use Patterns Among Cancer Patients
An observational study of Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by Thomas Jefferson University at 1 site in United States.
Trial summary
This study determines patterns of cannabis use among cancer patients. Information collected in this study may help doctors to understand patient use of cannabis therapy, their knowledge and experiences with this therapy, benefits and risks associated with its use, and whether or to what extent they are discussing it… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Survey Administration
- How many people
- 1,568 participants
- Where
- 1 siteUnited States
- Study dates
- 25 Feb 2021to 29 Oct 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who had at least one medical or radiation oncology appointment within last 3 years at Sidney Kimmel Cancer Center (SKCC) cancer centers
Who may be able to join
- Provide signed and dated informed consent form
- English speaking
- Willing to comply with all study procedures and be available for the duration of the study
- Any individual >= 18 years old
- At least one medical or radiation oncology appoint within the last 3 years at one of the SKCC cancer center campuses
Who cannot join
- Non-English speaking
- Not a cancer patient at one of the SKCC campuses
- Deceased
Trial locations and contacts
1 site in 1 country.
United States1 site
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
About this study
Official title: Determining Patterns of Cannabis Use Among Cancer Patients
This study determines patterns of cannabis use among cancer patients. Information collected in this study may help doctors to understand patient use of cannabis therapy, their knowledge and experiences with this therapy, benefits and risks associated with its use, and whether or to what extent they are discussing it with their health care providers.
Read the detailed description
PRIMARY OBJECTIVES:
- To identify the frequency, modes, and duration of cannabis use, assess experiences with obtaining and using cannabis, as well as reasons for use and perceived risks and benefits of its use among cancer patients who are undergoing or have recently completed active treatment.
Ia. To uncover disparities in use of cannabis, perceptions of use, and communication with providers among cancer patients who are identify as racial and ethnic minorities, have low health or digital literacy, are of older age or low socioeconomic status.
II. Among cancer patients with a known medical marijuana certification, assess the impact of cannabis on pain management, anxiety, anorexia, and quality of life, as well as their communication with their oncology team about their procurement and use of cannabis.
OUTLINE:
Patients complete a survey about knowledge and awareness of medical cannabis, perceived risks and benefits of cannabis, mode and frequency of use (if applicable), impact on cancer-related symptoms, patient provider discussions about cannabis, and demographic characteristics including health and digital literacy.
- Being tested
- Survey Administration
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Survey AdministrationOther
Complete a Survey
| Study group | Role | What they receive |
|---|---|---|
| Observational (survey) | Patients complete a survey about knowledge and awareness of medical cannabis, perceived risks and benefits of cannabis, mode and frequency of use (if applicable), impact on cancer-related symptoms, patient provider discussions about cannabis, and demographic characteristics including health and digital literacy. Receives: Other: Survey Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survey data analysis
Respondent demographics and clinical characteristics and survey responses
Measured: Up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2021
- Study start25 Feb 2021
- Primary completion29 Oct 2022
- Study completion29 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic and Lymphoid Cell NeoplasmStudies of the same condition, open and under way.
- More trials run by Thomas Jefferson UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 1,568 participants (actual)
Sponsor and investigators
- Lead sponsor
- Thomas Jefferson University
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05132842
- Sponsor's protocol ID
- 21F.175
- Other IDs
- P30CA056036-21S3, JT 16464
- Status last verified
- May 2025
- First submitted
- 2 Nov 2021
- Last updated
- 15 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determining Patterns of Cannabis Use Among Cancer Patients
- ClinicalTrials.gov ID
- NCT05132842
- Acronym / sponsor ID
- 21F.175
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,568 participants (actual)
- Lead sponsor
- Thomas Jefferson UniversityUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 25 Feb 2021 (actual)
- Primary completion
- 29 Oct 2022 (actual)
- Study completion
- 29 Oct 2022 (actual)
- First posted
- 24 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study determines patterns of cannabis use among cancer patients. Information collected in this study may help doctors to understand patient use of cannabis therapy, their knowledge and experiences with this therapy, benefits and risks associated with its use, and whether or to what extent they are discussing it with their health care providers.
Detailed description
PRIMARY OBJECTIVES:
- To identify the frequency, modes, and duration of cannabis use, assess experiences with obtaining and using cannabis, as well as reasons for use and perceived risks and benefits of its use among cancer patients who are undergoing or have recently completed active treatment.
Ia. To uncover disparities in use of cannabis, perceptions of use, and communication with providers among cancer patients who are identify as racial and ethnic minorities, have low health or digital literacy, are of older age or low socioeconomic status.
II. Among cancer patients with a known medical marijuana certification, assess the impact of cannabis on pain management, anxiety, anorexia, and quality of life, as well as their communication with their oncology team about their procurement and use of cannabis.
OUTLINE:
Patients complete a survey about knowledge and awareness of medical cannabis, perceived risks and benefits of cannabis, mode and frequency of use (if applicable), impact on cancer-related symptoms, patient provider discussions about cannabis, and demographic characteristics including health and digital literacy.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational (survey) | – | Other: Survey AdministrationPatients complete a survey about knowledge and awareness of medical cannabis, perceived risks and benefits of cannabis, mode and frequency of use (if applicable), impact on cancer-related symptoms, patient provider discussions about cannabis, and demographic characteristics including health and digital literacy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who had at least one medical or radiation oncology appointment within last 3 years at Sidney Kimmel Cancer Center (SKCC) cancer centers
Key inclusion criteria (5 listed)
- Provide signed and dated informed consent form
- English speaking
- Willing to comply with all study procedures and be available for the duration of the study
- Any individual >= 18 years old
- At least one medical or radiation oncology appoint within the last 3 years at one of the SKCC cancer center campuses
Key exclusion criteria (3 listed)
- Non-English speaking
- Not a cancer patient at one of the SKCC campuses
- Deceased
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Survey AdministrationComplete a Survey | Other | Observational (survey) |
Primary outcome
Survey data analysis
Time frame: Up to 12 months
Respondent demographics and clinical characteristics and survey responses
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2025.
Related trials for Hematopoietic and Lymphoid Cell Neoplasm
Not yet recruitingPhase 4
MACE and BTK Inhibitors
Hematologic Cancer, MACE
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by Thomas Jefferson University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survey data analysis (time frame: Up to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.